98%
921
2 minutes
20
Hypoxia serves as a fundamental component of the tumor microenvironment, exerting a crucial influence on tumor advancement. Nonetheless, a comprehensive examination of a prognostic signature linked to hypoxia in pancreatic cancer is notably absent, presenting an urgent necessity. Therefore, our objective was to create and authenticate a robust prognostic signature capable of predicting outcomes for pancreatic cancer. Initially, the Gene Set Enrichment Analysis (GSEA) database was used to obtain hypoxia-related genes, and prognostic genes were analyzed. Following this, we utilized the Lasso Cox regression model to construct the hypoxia risk score model. Pancreatic cancer patients were subsequently categorized into high- and low-risk groups according to the median risk score. Finally, the CIBERSORT technique was used to assess immune cell infiltration while examining the relationship between hypoxia and immune-related genes. Applying the Lasso Cox regression model, we pinpointed 2 significant genes, GYS1 and ALDOB. Following this, patients were categorized into hypoxia high-risk and low-risk groups. Notably, the low-risk cohort demonstrated a substantially heightened survival rate relative to the high-risk group. Further investigation into the immune microenvironment unveiled a greater prevalence of resting mast cells, monocytes, plasma cells, and naive CD4+ T cells in the low-risk category. In addition, we detected differences in the expression of 39 immune-related genes between the 2 groups. In summary, our study has established a predictive signature comprising molecular markers for forecasting the prognosis of pancreatic cancer patients.
Download full-text PDF |
Source |
---|
Comput Assist Surg (Abingdon)
December 2025
Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
To develop a DeepSurv model for predicting survival in pancreatic adenocarcinoma patients, evaluating the benefit of surgical versus non-surgical treatment across different stages, including stage IV subcategories. Clinical data were extracted from the SEER database (2000-2020). Patients were randomly divided into a model-building group and an experimental group.
View Article and Find Full Text PDFCancer Immunol Res
September 2025
University of Pennsylvania, Philadelphia, PA, United States.
Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4).
View Article and Find Full Text PDFEndocr Relat Cancer
September 2025
Endocrinology, Diabetology and Medical Andrology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
Bone metastases (BMs) are rare and late event in patients with neuroendocrine tumors (NETs). The aim of our study was to investigate clinical presentation and outcome of BMs in a large cohort of patients with NETs. A retrospective study was performed at two referral centers of Northern Italy (IRCCS Humanitas Research Hospital in Milan and S.
View Article and Find Full Text PDFJ Biomed Opt
December 2025
University of Toronto, Department of Medical Biophysics, Temerty Faculty of Medicine, Toronto, Ontario, Canada.
Significance: Tumor tissues exhibit contrast with healthy tissue in circular degree of polarization (DOP) images via higher magnitude circular DOP values and increased helicity-flipping. This phenomenon may enable polarimetric tumor detection and surgical/procedural guidance applications.
Aim: Depolarization metrics have been shown to exhibit differential responses to healthy and cancer tissue, whereby tumor tissues tend to induce less depolarization; however, the understanding of this depolarization-based contrast remains limited.
Front Oncol
August 2025
Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Introduction: Pancreatic adenocarcinoma (PAAD) is a highly aggressive malignancy characterized by a profoundly hypoxic tumor microenvironment, which fosters tumor progression and confers resistance to therapy The oncogenic regulator ID1has been implicated in PAAD malignancy, however, the mechanisms underlying hypoxia-induced stabilization of ID1 and the role of ubiquitin-mediated degradation remain poorly understood. Elucidating these pathways is essential for identifying novel therapeutic targets for PAAD.
Methods: In this study, we examined ID1 expression in PAAD tissues and cell lines using publicly available databases and in vitro models.